SPORES OF Aspergillus versicolor ISOLATED FROM INDOOR AIR OF A MOISTURE-DAMAGED BUILDING PROVOKE ACUTE INFLAMMATION IN MOUSE LUNGS

Microbial growth in moisture-damaged buildings has been associated with respiratory health effects, and the spores of the mycotoxin producing fungus Aspergillus versicolor are frequently present in the indoor air. To characterize the potential of these spores to cause harmful respiratory effects, mice were exposed via intratracheal instillation to a single dose of the spores of A. versicolor (1 × 10 5, 1 × 10 6, 5 × 10 6, 1 × 10 7, or 1 × 10 8 spores), isolated from the indoor air of a moisture-damaged building. Inflammation and toxicity in lungs were evaluated 24 h later by assessment of biochemical markers and histopathology. The time course of the effects was investigated with the dose of 5 × 10 6 spores for up to 28 days. The exposure to the spores increased transiently proinflammatory cytokine levels (tumor necrosis factor [TNF]α and interleukin [IL]-6) in bronchoalveolar lavage fluid (BALF). The cytokine responses were dose and time dependent. The highest cytokine concentrations were measured at 6 h after the dose, and they returned to the control level by 3 days. Moreover, the spores of A. versicolor recruited inflammatory cells into airways: Neutrophils peaked transiently at 24 h, macrophages at 3 days, and lymphocytes at 7 days after the dosing. The inflammatory cell response did not completely disappear during the subsequent 28 days, though no histopathological changes were seen at that time point. The spores did not induce expression of inducible nitric oxide synthase in lavaged cells. Only the highest spore dose (1 × 10 8) markedly increased serum IL-6, increased vascular leakage, and caused cytotoxicity (i.e., increased levels of albumin, total protein, lactate dehydrogenase [LDH], and hemoglobin in BALF) in the airways. In summary, the spores of A. versicolor caused acute inflammation in mouse lungs. This indicates that they have potential to provoke adverse health effects in the occupants of moisture-damaged buildings.

[1]  H. Nagura,et al.  Granulomatous lesions in the lung induced by inhalation of mold spores , 1994, Virchows Archiv.

[2]  D. Wang,et al.  [Production and characterization of sterigmatocystin]. , 1994, Wei sheng wu xue bao = Acta microbiologica Sinica.

[3]  John D. Spengler,et al.  Respiratory Symptoms and Housing Characteristics , 1994 .

[4]  E. Michaliszyn,et al.  Lack of involvement of nitric oxide in killing of Aspergillus fumigatus conidia by pulmonary alveolar macrophages , 1995, Infection and immunity.

[5]  J. Wedzicha.  Mechanisms of exacerbations. , 2001, Novartis Foundation symposium.

[6]  Tiina Reponen,et al.  Characterizing Mold Problem Buildings – Concentrations And Flora Of Viable Fungi , 1993 .

[7]  P. Morey,et al.  Building-associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor. , 1998, Journal of occupational and environmental medicine.

[8]  P. Thomas.  Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. , 2001, Immunology and cell biology.

[9]  Anne Hyvärinen,et al.  Fungi and actinobacteria in moisture-damaged building materials — concentrations and diversity , 2002 .

[10]  P. Morrow,et al.  Dust overloading of the lungs: update and appraisal. , 1992, Toxicology and applied pharmacology.

[11]  T. Standiford,et al.  Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. , 1999, Journal of immunology.

[12]  S. Abramson,et al.  Nitric Oxide: A Novel Mediator of Inflammation , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  P. Jorens,et al.  L-arginine-dependent nitric oxide synthase: a new metabolic pathway in the lung and airways. , 1993, The European respiratory journal.

[14]  Kari Reijula,et al.  Mycotoxins in Crude Building Materials from Water-Damaged Buildings , 2000, Applied and Environmental Microbiology.

[15]  J. Van Snick.  Interleukin-6: an overview. , 1990, Annual review of immunology.

[16]  R. Burnett,et al.  Respiratory health effects of home dampness and molds among Canadian children. , 1991, American journal of epidemiology.

[17]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[18]  P. Barnes,et al.  EXHALED NITRIC OXIDE IN MONITORING ASTHMA , 1997 .

[19]  A. Mencacci,et al.  Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. , 2001, The Journal of infectious diseases.

[20]  S M Hunt,et al.  Damp housing, mould growth, and symptomatic health state. , 1989, BMJ.

[21]  D. Smith,et al.  Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-alpha and GM-CSF in neutrophil recruitment. , 1999, Medical mycology.

[22]  B. Crook,et al.  Fungal and actinomycete spores as pollutants of the workplace and occupational allergens. , 1988, The Annals of occupational hygiene.

[23]  D. Strachan.  Damp housing and childhood asthma: validation of reporting of symptoms. , 1988, BMJ.

[24]  W. Sorenson,et al.  Fungal spores: hazardous to health? , 1999, Environmental health perspectives.

[25]  A. Seaton,et al.  Resistance of spores of Aspergillus fumigatus to ingestion by phagocytic cells. , 1987, Thorax.

[26]  A Nevalainen,et al.  Home dampness, moulds and their influence on respiratory infections and symptoms in adults in Finland. , 1996, The European respiratory journal.

[27]  S. Gravesen,et al.  Health implications of fungi in indoor environments. , 1994 .

[28]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[29]  Anne Hyvärinen,et al.  Temporal and spatial variation of fungal concentrations in indoor air , 2001 .

[30]  V. Kosma,et al.  Inflammatory responses in mice after intratracheal instillation of spores of Streptomyces californicus isolated from indoor air of a moldy building. , 2001, Toxicology and applied pharmacology.

[31]  B. Flannigan,et al.  Mould in buildings: the air spora of domestic dwellings , 1988 .

[32]  Xianglin Shi,et al.  Molecular Mechanism of Tumor Necrosis Factor-α Production in 1→3-β-Glucan (Zymosan)-activated Macrophages* , 2001, The Journal of Biological Chemistry.

[33]  A. Mencacci,et al.  Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. , 1998, The Journal of infectious diseases.

[34]  T. Evans,et al.  Nitric oxide, the biological mediator of the decade: fact or fiction? , 1997, The European respiratory journal.

[35]  Tiina Reponen,et al.  The indoor air quality in finnish homes with mold problems , 1991 .

[36]  A. Hyvärinen,et al.  Production of proinflammatory mediators by indoor air bacteria and fungal spores in mouse and human cell lines. , 2003, Environmental health perspectives.

[37]  K. Donaldson,et al.  Nonneoplastic lung responses induced in experimental animals by exposure to poorly soluble nonfibrous particles. , 2000, Inhalation toxicology.

[38]  P. Thomas.  Tumour necrosis factor‐α: The role of this multifunctional cytokine in asthma , 2001 .

[39]  M. Toivola,et al.  Induction of cytotoxicity and production of inflammatory mediators in raw264.7 macrophages by spores grown on six different plasterboards. , 2001, Inhalation toxicology.

[40]  Ragnar Rylander,et al.  (1→3)-β-d-glucan — relationship to indoor air-related symptoms, allergy and asthma , 2000 .

[41]  V. Kosma,et al.  Inflammatory potential of the spores of Penicillium spinulosum isolated from indoor air of a moisture-damaged building in mouse lungs. , 2002, Environmental toxicology and pharmacology.

[42]  J. Hibbs,et al.  Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.

[43]  R. Rylander,et al.  (1-->3)-beta-D-glucan - relationship to indoor air-related symptoms, allergy and asthma. , 2000, Toxicology.

[44]  P. Barnes.  Potential novel therapies for chronic obstructive pulmonary disease. , 2001, Novartis Foundation symposium.

[45]  B. Brunekreef,et al.  Respiratory symptoms in damp homes , 1989, Allergy.